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Abstract
Background: In recent years, there has been tremendous growth and interest in translational research, particularly
in cancer biology. This area of study clearly establishes the connection between laboratory experimentation and
practical human application. Though it is common for laboratory and clinical data regarding patient specimens to
be maintained separately, the storage of such heterogeneous data in one database offers many benefits as it may
facilitate more rapid accession of data and provide researchers access to greater numbers of tissue samples.
Description: The Thoracic Oncology Program Database Project was developed to serve as a repository for well-
annotated cancer specimen, clinical, genomic, and proteomic data obtained from tumor tissue studies. The TOPDP
is not merely a library–it is a dynamic tool that may be used for data mining and exploratory analysis. Using the
example of non-small cell lung cancer cases within the database, this study will demonstrate how clinical data may
be combined with proteomic analyses of patient tissue samples in determining the functional relevance of protein
over and under expression in this disease.
Clinical data for 1323 patients with non-small cell lung cancer has been captured to date. Proteomic studies have
been performed on tissue samples from 105 of these patients. These tissues have been analyzed for the expression
of 33 different protein biomarkers using tissue microarrays. The expression of 15 potential biomarkers was found to
be significantly higher in tumor versus matched normal tissue. Proteins belonging to the receptor tyrosine kinase
family were particularly likely to be over expressed in tumor tissues. There was no difference in protein expression
across various histologies or stages of non-small cell lung cancer. Though not differentially expressed between
tumor and non-tumor tissues, the over expression of the glucocorticoid receptor (GR) was associated improved
overall survival. However, this finding is preliminary and warrants further investigation.
Conclusion: Though the database project is still under development, the application of such a database has the
potential to enhance our understanding of cancer biology and will help researchers to identify targets to modify
the course of thoracic malignancies.
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There is considerable interest in understanding the
pathophysiology contributing to cancer. One modern
research paradigm suggests that understanding the
genomic and proteomic alterations leading to cancer
will lead to enhanced cancer prevention, detection, and
targeted molecular therapeutic strategies. Capturing
information regarding the nature of such alterations has
been accelerated with the completion of the human gen-
ome project. Since then, scientists have been able to
more rapidly and efficiently identify genetic alterations
and consequently, the fields of genomics and proteomics
have grown exponentially.
The identification of genetic and proteomic altera-
tions, however, is only one part of the equation. It is
essential to explore the functional relevance of these
alterations as they relate to tumorigenesis in order to
progress from an interesting observation to a beneficial
therapeutic strategy. Growing interest in translational
research has spurred the growth of biorepositories, such
as the NCI OBBR [1], which are large libraries of
banked biological specimens accessible to researchers
for the study of a variety of diseases. Agencies from the
national, state, private, and academic levels have all been
actively engaged in the development of biorepositories
to facilitate translational research.
A major limitation to conducting translational
research is that basic science and clinical data are often
stored in different databases [2]. This makes it challen-
ging for basic science researchers to access clinical data
to perform meaningful analysis. Additionally, research is
often limited to readily available samples that may not
be representative or sufficient in number to support or
r e f u t eas p e c i f i ch y p o t h e s i s .T h ep r o m i s eo fm o d e r n
biorepositories is that researchers can access large quan-
tities of aggregated and verified data which can then be
used to validate previously generated hypotheses or sti-
mulate new hypothesis-driven studies [3].
The potential of modern translational research
prompted the development of the Thoracic Oncology
Program Database Project (TOPDP). The aims of this
endeavor were to: (1) create a platform to house clinical,
genomic, and proteomic data from patients with thoracic
malignancies; (2) tailor the platform to meet the needs of
clinical and basic science researchers; and (3) utilize the
platform in support of meaningful statistical analysis to
correlate laboratory and clinical information. The thor-
acic oncology database is unique from other bioreposi-
tory systems because it is not merely a listing of available
tissue samples but rather offers a glimpse into the pro-
teomic and genomic characterization of these tissues.
Herein, we demonstrate how our thoracic oncology
database can be used for data mining and exploratory
analysis. This report will focus on the proteomic analysis
of non-small cell lung cancer (NSCLC) identified within
the database as a case study of how the database may be
utilized. In 2010, there were estimated to be 222,520
new cases and 157,300 deaths from lung cancer [4].
Lung cancer has traditionally been dichotomized into
two groups based on the histological features of the
tumor: small cell and non-small cell lung cancer.
NSCLC is the more common of the two sub-types of
lung cancer, constituting 85% of cases [5,6]. Further-
more, studies have shown that NSCLC has less of a cau-
sal association with smoking than other forms of lung
cancer [7] and therefore more than behavioral modifica-
tion may be necessary to alter the course of this disease.
Given the enormity of its impact, many in the research
community are dedicated to better characterizing
NSCLC.
Access to a comprehensive and validated database
such as this is valuable to translational cancer research-
ers who may use this database to look at data from a
large number of samples. Studies based on larger sample
sizes may help validate hypotheses not generally sup-
ported based on experiments using limited samples.
Furthermore, they may refute conclusions based on
experiments which may have been biased and under-
powered because of selected and limited samples. Analy-
sis of aggregated data from databases such as ours will
promote better understanding of complex diseases
which in turn will lead to more clearly defined targets
for cancer prevention, detection, and treatment.
Construction and Content
Subjects
Standard for subject enrollment
Clinical data were obtained from subjects enrolled under
two IRB approved protocols: (a) Protocol 9571 - a pro-
spective protocol designed to obtain tissue samples from
patients who will have a biopsy or surgery at the Uni-
versity of Chicago Medical Center for known or poten-
tial malignancies, and (b) Protocol 13473 - a
retrospective protocol to access tissue samples already
obtained through routine patient care which have been
stored at the University of Chicago Medical Center.
Under Protocol 9571, patients were consented during
scheduled appointments in the thoracic oncology clinic.
Patients who previously underwent biopsy or surgery at
the University of Chicago were consented to protocol
13473 during subsequent clinic visits. Patients who were
expired were exempt and their tissues were included
under an exempt protocol.
Inclusion Criteria
Participants were selected if they were under the care of
an oncologist at the University of Chicago Medical Cen-
ter for a known or potential thoracic malignancy.
Healthy controls were not included in this study. All
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mary cancer that was pathologically confirmed. Subjects
were adults over the age of 18 years.
Clinical Data Collection Protocol
Clinical information for consented or expired subjects was
obtained through medical chart abstraction and entered
into the database by the data curator. For quality assur-
ance, clinical information was only added to the database
following confirmation of the data in the patient’s chart.
Tissue Samples
Specimen Collection Protocol
Tissues of interest were malignant and originating in the
thoracic cavity. Tissues containing a known or suspected
malignancy were obtained during standard clinical care
through a biopsy or surgery. No additional tissue, outside
of what was necessary for a diagnostic workup, was speci-
fied under this protocol. The attending pathologist
ensured that the amount of tissue collected was sufficient
for clinical purposes. However, if additional tissue, not
essential for the diagnostic process was available, this tis-
sue was banked. When available, samples of both normal
and tumor tissues were collected from each subject.
Pathology Tissue Banking Database
All records of biological specimens obtained under these
protocols were maintained in the pathology department
within eSphere, a pathology tissue banking database. The
eSphere database was developed in order to catalogue
detailed information about the biospecimens. The samples
were described by procedure date, specimen type (fresh
frozen, paraffin embedded), location of the tumor, type of
tissue (tumor, non-tumor), and specimen weight. The
eSphere database uses barcode identification in order to
ensure patient confidentiality and to minimize errors. The
system is password protected and it is only available to
IRB approved users within the medical center.
Human Subject Protection
With the exception of expired patients for whom an IRB
waiver was granted, only subjects for whom written
informed consent was obtained were included in the
study. The database is password protected and access
was limited to clinical staff directly responsible for
maintaining the database. Individual investigators per-
forming molecular studies did not have access to patient
identifying information (medical record number, name,
date of birth). In compliance with HIPAA rules and reg-
ulations, all reports generated using the database were
de-identified. The protocol was approved by the IRB at
the University of Chicago.
Development of the Database
Informatics Infrastructure
To facilitate data storage and analysis, an informatics
infrastructure was developed utilizing Microsoft Access
as the primary repository of clinical and laboratory data
(Figure 1). This program was selected based on a num-
ber of favorable characteristics including its ease of
search and query functions. Other benefits of Microsoft
Access include its large storage capacity and its ability
to form relationships among multiple tables, thereby
eliminating the need for data redundancy. Finally,
Microsoft Access is readily available to most researchers.
Though other database technologies are not necessarily
prohibitive, it was important for the database team to
select a program that could reduce barriers in collabor-
ating with outside institutions who may also be inter-
ested in database initiatives.
Identification of Data Elements
The variables captured in the database were identified
based on needs expressed by both clinical and basic
science researchers. These elements respect the stan-
dards which emerged from the NCI Common Data Ele-
ments Committee [8]; however, they expand upon those
standards to meet the needs of the research team. Vari-
ables of interest were established based on leadership
provided by researchers from the department of hema-
tology/oncology, pathology, surgery, radiation oncology,
pharmacy, bioinformatics, and biostatistics. Standards
used to establish the variables of interest were also
based on precedent set by the Cancer Biomedical Infor-
matics Grid (CaBIG) [9], the NAACCR [10] Data Stan-
dards for Cancer Registries, and the American Joint
Committee on Cancer (AJCC) Staging Manual [11].
Development of Tables
Variables of interest were captured within four primary
tables in the Access database: the Patients table, the
DNA Specimens tables, the TMA table, and the Sample
Data table. Each table captures different aspects of
related information in a manner that reduces redun-
dancy. For example, the main table in the database is
the Patients table, which contains all clinically relevant
information regarding the subject. This includes demo-
graphic information, clinically relevant tumor informa-
tion including histology, stage, grade, treatment history,
epidemiological factors, and patient outcome.
The DNA specimens table captures the genomic infor-
mation characterizing mutations in tissue obtained from
the subjects identified in the Patients table. This table is
linked by the medical record number to the Patients
table and thus there is no need to annotate tissue infor-
mation such as histology, stage, and grade in the DNA
Specimens table as that information is already captured.
The TMA table captures proteomic data from tissue
samples that have been analyzed by tissue microarray
(TMA). To facilitate the large-scale study of proteins
expressed within the tumor, tissue microarrays were
constructed as previously described [12]. The TMA
were built using the ATA-27 Arrayer from Beecher
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biopsied tumor and adjacent normal tissues were pre-
c i s e l yo r g a n i z e di n t oag r i da n de m b e d d e di np a r a f f i n
(representative image of TMA is shown in Figure 2).
Paraffin blocks were separated so slices could be evalu-
ated for the expression of various proteins using immu-
nohistochemistry (IHC). IHC staining was performed
using standard techniques and commercially available
antibodies (see Appendix, Table 1).
IHC was scored on a semi-quantitative scale by a
pathologist trained in this technique. All slides were
reviewed by two independent pathologists. Each pathol-
ogist scored the tissue on a scale of 0 to 3 reflecting the
degree of staining, with greater staining serving as a
proxy for higher protein expression.
Two measures, the percent and intensity of IHC stain-
ing, were used to describe the level of protein expres-
sion in a tissue sample. Percent staining refers to the
fraction of one core which stains positively for a particu-
lar protein. A core with less than 10% staining is scored
a 1, between 11 and 50% staining is scored a 2, and
greater than 50% staining is scored a 3. Intensity of
Figure 1 Thoracic Oncology Program Database Project schematic. Conceptual schematic depicting the multiple components contributing
to the program.
Figure 2 Tissue Microarray (TMA). In a TMA, cores of tumor and
adjacent normal tissue are removed from tissue embedded in
paraffin blocks. Cores are arranged in an array and slices are stained
using antibodies to assess the expression of proteins of interest.
Table 1 Source of Antibodies
Antibody Vendor
c-Met Zymed
p-Met 1003 Biosource
p-Met 1349 Biosource
p-Met 1365 Biosource
p-Met Triple Biosource
HGF R&D systems
Ronb Santa Crutz
p-Ronb Santa Crutz
Her3 Santa Crutz
EphA2 Santa Crutz
EphB4 Vasgen Therapeutics
Fibronectin DAKO
b-catenin Zymed
E-cadherin Zymed
EzH2 Zymed
Snail AVIVA Systems Biology
Vimentin DAKO
Paxillin Salgia Lab
GR Novocastra
ERb Biogenex
PKCB-b1 Santa Crutz
PKCB-b2 GeneTex
Antibodies were purchased from the listed manufacturers.
Surati et al. Journal of Clinical Bioinformatics 2011, 1:8
http://www.jclinbioinformatics.com/content/1/1/8
Page 4 of 11staining compares the relative intensity of staining of
o n ec o r eo faT M At ot h a to fac o n t r o lc o r eo nt h e
same slide. A score of 1 indicates faint staining, 2 indi-
cates medium intensity staining, and 3 indicates dark
staining. Furthermore, the pathologist is also able to
visually assess the localization of predominant protein
expression under the microscope and may categorize
staining as being nuclear, cytoplasmic, or membranous.
Thus, one protein may be characterized by multiple
values.
Finally, the Sample Data table was developed in order
to facilitate a link between the medical record number
and the sample pathology number. The medical record
number is unique to each patient while the sample
pathology number is unique to each specimen. This
table allows the researcher to rapidly determine the
number of specimens catalogued in the database for
each subject.
Query
With relationships established among the tables within
the database, a query can be generated to combine
related data. The query was performed by the data man-
ager who exported data to the requesting researcher. It
is important to note that exported information is de-
identified by removing the medical record number,
patient’s name, and date of birth.
Statistics
We have used the database to correlate proteomic infor-
mation with clinical parameters for patients with non-
small cell lung cancer. Within this database, a unique
patient often had several TMA punches captured within
the TMA table for a particular protein, reflecting the
multiple types of tissue obtained for each patient.
Therefore, samples were grouped according to tissue
source: tumor tissue, normal tissue, and metastatic tis-
sue for each patient with TMA data within the database.
An averaged protein expression score was calculated
for all available normal and tumor samples for each
patient (i.e., replicates of the same type of tissue for a
given patient were averaged) for each protein studied in
the TMA database. Averaged “tumor tissue” scores
included all samples that were isolated from the center
of the tumor. Averaged “normal samples” included sam-
ples described as “adjacent normal”, “alveoli normal”
and “bronchi normal”.
A Wilcoxon signed-ranks test was used to compare
protein expression between tumor and matched normal
tissue for each patient. Differences were considered sta-
tistically significant for an a less than or equal to 0.05.
Heat maps were developed using R (R version 2.11.1,
The R Foundation for Statistical Computing) to graphi-
cally display tumor protein expression so as to more
readily identify variability in expression. Mean protein
expression for a particular biomarker was calculated and
was stratified by histology and also by stage. A heat map
was generated for each parameter.
Proteins were clustered ap r i o r iin the heat maps by
their functional families: receptor tyrosine kinase (RTK),
epithelial mesenchymal transition (EMT), non-receptor
tyrosine kinase (non-RTK), protein kinases (PK), and
histone modifiers (HM) (Table 2). Groupings were not
based on formal cluster analysis. Differences in protein
expression among protein families were compared using
Mann-Whitney U testing with significant differences
occurring at a p-value ≤ 0.05.
Finally, tumor samples were independently studied to
determine the impact of protein expression on survival.
Multivariate survival analysis was performed using a
Cox (1972) regression model in order to control for the
influence of stage of diagnosis and age at diagnosis. Sta-
tistical analysis was performed using SPSS software
(SPSS Standard version 17.0, SPSS).
Utility
Patient Characteristics
At the time of compilation of this study, a total of 2674
unique patients were entered into the database. Patients
with non-small cell lung cancer comprise the majority
of cases annotated within the database. Other cancers
contained in the database include small cell lung cancer,
mesothelioma, esophageal cancer, and thymic carci-
noma, amongst others. Descriptive characteristics of the
patients captured within the database were most often
obtained retrospectively via chart abstraction. Demo-
graphic and clinical data for the 1323 NSCLC cases are
summarized in Table 3.
TMA and Analysis
A total of 867 cores from 105 unique patients were ana-
lyzed for their level of expression for 17 different pro-
teins using tissue microarray (TMA). Demographic and
clinical data for the NSCLC patients with proteomic
data is summarized in Table 3. These patients are com-
parable to the NSCLC dataset in terms of gender, racial,
Table 2 Protein Functional Families
RTK EMT NonRTK PK HM
Met b-catenin ER PKC-b1 EzH2
Ron E-cadherin GR PKC-b2
EphA2 Fibronectin
EphB4 Snail
Her3 Vimentin
HGF Paxillin
Proteins captured in the database were grouped by their functional families:
Receptor Tyrosine Kinase (RTK), Epithelial Mesenchymal Transition (EMT), Non-
receptor Tyrosine Kinase (NonRTK), Protein Kinase (PK), and Histone Modifier
(HM).
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at diagnosis, and median survival.
For any given protein biomarker, the database con-
tained tumor and corresponding normal data for 50 to
100 patients. Though only 17 proteins were included in
this analysis, a total of 33 protein biomarkers were eval-
uated. This is due to the fact that for certain proteins,
different protein localizations (nuclear, membranous,
and cytoplasmic) were compared between tumor and
matched normal samples. Furthermore, for a given pro-
tein, both a protein percent staining score and a protein
intensity staining score may have been calculated. All of
these values serve as a proxy for the degree of protein
expression and thus are included in the analysis.
The protein expression of tumor samples was com-
pared with protein expression from normal tissue from
the same patient. There were 15 potential biomarkers
for which expression was significantly higher in tumor
tissue (p < 0.05), 2 protein biomarkers for which expres-
sion was greater in normal tissue, and 16 protein bio-
markers for which expression was not significantly
different between the two tissue types (Table 4).
A few interesting trends emerged. For c-Met, there
was greater expression of the protein in the tumor than
in the matched normal tissue for the cytoplasmic locali-
zation of the protein but the reverse was true for the
membranous and nuclear distributions. For p-Met 1003,
the cytoplasmic distribution was greater in tumor than
in matched normal tissue, but there was no difference
in p-Met 1003 nuclear expression. Finally, for p-Met
1349, p-Ron, and Her3, tumor expression was greater
for both the cytoplasmic and nuclear localizations than
matched normal tissue. This suggests that though pro-
tein expression may be generally greater in tumor tissue,
it may selectively be observed in different parts of the
cell.
For protein biomarkers such as fibronectin, ß-catenin,
E-cadherin, and EzH2 the relative percentage of the
tumor core which stained positively for a given biomar-
ker was greater than matched normal tissue. However
the intensity of biomarker staining did not differ. There
is evidence to suggest that percentage staining may be a
marker which is better correlated with relevant tumor
endpoints and thus may be preferred to intensity values
[13]. Differential percent staining but the lack of a dif-
ferential intensity staining suggests that tumor tissue is
Table 3 Patient Demographics
Number of Cases (%)*
Entire
Database
TMA only Heat map
only
Gender
Male 688 (52) 63 (60) 46 (60)
Female 635 (48) 42 (40) 31 (40)
Race
Caucasian 587 (44) 63 (60) 51 (66)
African American 377 (28) 34 (32) 23 (30)
Other 38 (3) 2 (2) 3 (4)
Non-Specified 321 (24) 6 (6) n/a
Histology
Adenocarcinoma 603 (46) 58 (55) 51 (66)
Large Cell Carcinoma 75 (6) 18 (17) 15 (19)
Squamous Cell
Carcinoma
338 (26) 15 (14) 11 (14)
NSCLC Non-Specified 307 (23) 14 (13) n/a
Stage
I 379 (29) 49 (47) 37 (48)
II 123 (9) 12 (11) 8 (10)
III 261 (20) 32 (30) 27 (35)
IV 173 (13) 6 (6) 5 (6)
Non-Specified 384 (29) 6 (6) n/a
Vital Status
Alive 537 (41) 32 (30) 24 (31)
Deceased 452 (34) 71 (68) 53 (69)
Unknown 334 (25) 2 (2) n/a
Mean Age at Diagnosis 64 years 61 years 61 years
Median Survival 17 months 16
months
17 months
Total NSCLC Cases 1323 105 77
*Due to rounding, percentages may not sum to 100.
To date, 1323 NSCLC patients have been captured in the database. A subset
of these have TMA data (n = 105) and a further subset of patients were
included in the heat map analysis.
Table 4 Comparison of Protein Expression between
Tumor and Normal Tissue
Tumor > Normal Normal > Tumor Tumor = Normal
c-Met Cytoplasmic c-Met
Membranous
p-Met 1003 Nuclear
p-Met 1003
Cytoplasmic
c-Met Nuclear p-Met 1365 Nuclear
p-Met 1349
Cytoplasmic
p-Met Triple
Nuclear
p-Met 1349 Nuclear Ron Membranous
HGF Cytoplasmic Fibronectin Intensity
p-Ron Cytoplasmic Β-catenin Intensity
p-Ron Nuclear E-cadherin Intensity
Her3 Cytoplasmic Snail Percentage
Her3 Nuclear Snail Intensity
EphA2 Vimentin Percentage
EphB4 Paxillin
Fibronectin Percentage GR
b-catenin Percentage ER b
E-cadherin Percentage PKC-b1
EzH2 Percentage PKC-b2
EzH2 Intensity
Protein expression was compared between tumors and matched control
tissue. Certain proteins were found to differentially expressed, while others
were not. These differences were statistically significant. Proteins are
organized by functional families represented by different fonts.
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in focal areas of tumor.
Heat map analysis
Data from a total of 77 patients with tumor protein
expression data, histologic categorization, and stage
categorization were included in the heat map displays.
These patients were a subset of the 105 patients
included in the TMA analysis and were selected because
they had protein expression data within each of the pro-
tein families. These patients are comparable to the
TMA analysis group in terms of gender, racial, histolo-
gic, and stage characterization, vital status, mean age at
diagnosis, and median survival (Table 3).
Based on the heat maps, differential expression pat-
terns were noted. Firstly, when protein expression was
categorized by histology, the non-RTK, PK, and HM
f a m i l i e so fp r o t e i n st e n d e dt ob em o r eh i g h l ye x p r e s s e d
than RTK and EMT proteins in tumor tissue (p = 0.05)
(Figure 3). When the proteins were separated by stage, a
similar pattern emerged (p = 0.00) (Figure 4). Notably,
t h e s es a m ep a t t e r n sw e r er e p r o d u c e dw h e na n a l y z i n g
matched normal tissue (p = 0.001 and p = 0.002, respec-
tively). This may be due to a few reasons. Differences in
antibodies used to stain for various proteins may pro-
vide a technical consideration when comparing expres-
sion between different proteins. Furthermore, as there
were more members of the RTK and EMT families than
t h eo t h e rg r o u p s ,a v e r a g e dR T Ka n dE M Tc o u l dh a v e
lower values due to data reduction.
In addition, there was a trend towards higher protein
expression in adenocarcinoma and large cell carcinoma
than in squamous cell carcinoma; however, this differ-
ence was not statistically significant (one way ANOVA;
p = 0.16). This was suggestive of but not diagnostic for
global protein over-expression within these histologies.
There was no difference among the stages related to
overall protein expression (one way ANOVA; p = 0.92).
Survival Analysis
To study the relationship between protein expression
and survival in non-small cell lung cancer, expression
data from 33 protein biomarkers were studied using
both univariate and multivariate analyses. Of the pro-
teins studied, only one was found to have a nominally
statistically significant association with survival, the glu-
cocorticoid receptor (GR).
In univariate survival analysis, a cumulative survival
curve was calculated using the Kaplan-Meier method.
Protein expression was stratified into two categories:
under- and over-expression. Protein expression was
dichotomized at the median tumor GR expression value
of 2.13. The survival difference between the two protein
expression curves was assessed using a log-rank test.
The median overall survival time for patients with GR
under-expression was 14 months, while the median
Figure 3 Heat map based on tumor histology.A v e r a g e dt u m o r
protein expression values for given proteins are stratified by tumor
histology: adenocarcinoma (AC), squamous cell carcinoma (SqCC),
and large cell carcinoma (LCC).
Figure 4 Heat map based on tumor stage.A v e r a g e dt u m o r
protein expression values for selected proteins are stratified by
tumor stage at diagnosis.
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s i o nw a s4 3m o n t h s .T h ed i f f e r e n c ei ns u r v i v a lt i m e
between the two groups was statistically significant (p =
0.04) (Figure 5).
Since known prognosticators could confound the asso-
ciation between protein expression and survival time, a
multivariate Cox regression model was used to predict
the impact of protein expression on survival after con-
trolling for stage of disease and the patient’sa g ea t
diagnosis.
T h e r ew e r e9 3p a t i e n t sf o rw h o mt h ee x p r e s s i o no f
the protein GR had been studied. Using a Cox regres-
sion model, a statistically significant hazard ratio of 0.76
(95% CI: 0.59, 0.97) was calculated (p = 0.03). Therefore,
GR over-expression was associated with increased
patient survival. Similar find i n g sw e r ep r e v i o u s l yn o t e d
in patients with advanced non-small cell lung cancer
[14]. It should be noted, however, that after adjusting
for multiple comparisons (33 protein biomarkers were
evaluated), this finding does not reach statistical signifi-
cance. Thus these results should be viewed as hypoth-
esis-generating only, in need of further confirmation in
an independent dataset.
Discussion
Given that lung cancer is the leading cause of cancer
related death in the United States, there is tremendous
interest in identifying markers which may not only help to
better elucidate oncogenic pathways but also lead to clini-
cally relevant targets involved in the diagnosis and treat-
ment of this disease. Though much research has been
invested into the discovery of such biomarkers, often they
have proved to be of limited clinical utility [15].
While genomics research continues to play an impor-
tant role, increasing emphasis has been placed on
proteomics in the area of biomarker research [15].
Often proteomic studies will focus on the expression of
one protein of interest or one family of proteins and
will relate these outcomes to relevant clinical endpoints
[14,16-19]. While this is important work, it is our belief
that by developing a database in which multiple biomar-
kers and their interaction sm a yb es t u d i e ds i m u l t a -
neously, we will be better equipped to understand the
complex interplay among various proteins and its rela-
tion to oncogenesis. This may lead to the hypothesis
generation necessary to identify a relevant target or mul-
tiple targets in the cancer pathway.
A view of the descriptive data presented in the heat
maps suggests that proteins in the non-RTK, PK, and
HM families are more highly expressed in tumor tissues
than proteins from the RTK and EMT families. However,
when the comparison is made between tumor and nor-
mal tissues, predominantly RTK proteins appear to be
differentially expressed between the two tissue types.
This suggests that though non-RTK, PK, and HM pro-
teins may be more highly expressed globally, RTK pro-
teins may make for better clinical targets because of their
discrepant expression. This finding further validates the
notion of MET [20] as a therapeutic target in lung cancer
and should reinforce research regarding this potential
biomarker in the treatment of non-small cell lung cancer.
The data analyzed here highlights the potential of the
TOPDP as a translational research tool. The data
demonstrates that large amounts of information can be
readily accessed and analyzed to support translational
efforts. The formation of such a system promotes both
hypothesis-driven and exploratory studies. However, it is
important to understand the limitations of this database
project in its present form. Furthermore, additional stu-
dies will be necessary to determine the functional
importance of identified proteins.
A major consideration to make when interpreting the
results of the exploratory analyses done on the tissue
microarrays has to do with sample size. While the data-
base has information on over 2500 patients, it is still
relatively small compared with most databases. Further-
more, since each protein biomarker studied may have
only had expression data from 50-100 patients for a par-
ticular type of cancer, there may not be a large enough
sample size to detect the impact of protein under- or
over-expression on clinical endpoints. Another limita-
tion is that tumor tissues were not studied for every
protein of interest. Any given tumor sample may have
only been studied for the expression of a limited num-
ber of proteins. Though cumbersome and costly, it
would be valuable to have proteomic analysis for every
protein of interest for every patient within the database.
Given its focus on malignancy, an inherent caveat of
the database is the lack of true normal controls. It can
Figure 5 Kaplan Meier Survival Curve for GR. Survival curves
were dichotomized on the median expression value of the
Glucocorticoid receptor (GR). Higher expression of GR was
associated with greater overall survival. Tick marks represent
censored data points.
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subject to stresses different from other tissues and thus
does not represent true normal tissues. While this may
be true, it is less common to have biopsy or surgically
resected tissue from an individual outside the course of
their cancer workup and treatment. Although it may be
beneficial to bank normal tissue from healthy indivi-
duals, this is not a reasonable endeavor at this time. The
caveat of “normalcy” is important and warrants consid-
eration in the process of comparing “tumor” and “nor-
mal” tissues within our biorepository. It is also
important to note that since tissues were obtained dur-
ing the course of a patient’s diagnostic or therapeutic
care, not all patients had both “tumor” and “normal” tis-
sue samples available in the biorepository.
As this has been both a retrospective and prospective
initiative, the shortcomings of chart abstraction have
become evident. The availability of dictated clinic notes
is variable as many paper notes have not yet been
entered into the electronic medical record system. This
limits the amount of data that can be entered in the
database by the data curator. In addition, if the physi-
cian dictating clinic notes did not describe epidemiologi-
cal factors such as smoking history, these variables were
not documented for all patients. Fortunately, moving
forward, detailed questions will be asked of patients
enrolled in the prospective protocol and as such, more
detailed information will be available.
Another limitation of the database is that detailed
vital status information is not available on all patients.
Since patient medical charts are not linked to external
sources, if the patient expires outside of our institu-
tion, our system is not aware of this event. Thus some
patients may incorrectly be listed as living. In order to
obtain more accurate vital status information, our
team has used the Social Security Death Index [21] to
periodically determine the vital status of patients
within our database. Though efforts are made to
update the database every six months, it is important
to have an automated means of updating vital status.
Similarly, for the purposes of survival analyses, the
date of last contact with our institution was used to
censor living patients. Given that a patient may have
transferred care to an outside institution and have
died, censoring the survival time at the date of last
contact may bias our estimates.
Finally, while the database reasonably captures infor-
mation about a patient’s treatment course, it could do
so with greater detail. Differences in the types and tim-
ing of therapy may serve as important covariates in mul-
tivariate analyses. It is important to capture relevant
detail regarding the complexity of a patient’s treatment
course. The database team is already in the process of
advancing the database to make this capability possible.
Conclusion
The database developed as part of the Thoracic Oncol-
ogy Program Database Project serves as an example of
the collective effort towards advancing translational
research. This database is unique in that it is not merely
al i s to fs t o r e ds p e c i m e n sb u tr a t h e rp r o t e o m i ca n d
genomic characterizations are captured within the data-
base as well. In this manner, proteomic data can be ana-
lyzed in aggregate and is not limited to the small sample
sizes common to most basic science research. With
additional sample size, data is more robust and real
trends may be identified.
In an effort to further increase sample size, the stan-
dard operating procedure and database template has
been made available online at http://www.ibridgenet-
work.org/uctech/salgia-thoracic-oncology-access-tem-
plate. By freely sharing the design of this database with
collaborators at outside institutions, it is anticipated that
they may develop their own database programs. The
development of such databasesr e q u i r e st h ee s t a b l i s h -
ment of clearly defined protocols detailing methods by
which tissue samples are collected and clinical informa-
tion are annotated. This will in turn ensure high speci-
men quality as well as consistency of clinical
information obtained. With variables captured identi-
cally across geographic locales, data may be reliably
combined [22]. There are many benefits for inter-insti-
tutional collaboration. Not only will this increase sample
size and increase statistical power for proteomic and
genomic studies [23], this will also increase the diversity
of the patient sample captured within the database. In
this manner, disparities in cancer outcomes may be
further explored.
Though promoting collaboration is an important
priority of the database team, the decision was made not
to make this a web-based database. Freely allowing out-
side collaborators to contribute to one shared database
raises important IRB and intellectual property related
concerns. Thus, this database is maintained within our
institution and when outside collaborators have devel-
oped their own databases and would like to share data,
appropriate steps can be taken with specific institutional
regulatory bodies.
Through the established infrastructure of the Thor-
acic Oncology Program Database Project, clinical and
basic science researchers are able to more efficiently
identify genetic and proteomic alterations that contri-
bute to malignancy. The evolution of bioinformatics in
practice will further promote the development and
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Page 9 of 11translation of important laboratory findings to clinical
applications. Accurate, accessible, and comprehensive
data facilitates better research and will promote the
development of more effective solutions to complex
medical diseases.
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